{
    "clinical_study": {
        "@rank": "120903", 
        "arm_group": [
            {
                "arm_group_label": "group KO", 
                "arm_group_type": "Experimental", 
                "description": "(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)"
            }, 
            {
                "arm_group_label": "group DO", 
                "arm_group_type": "Active Comparator", 
                "description": "(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators performed this study to investigate pain prevention of preoperative\n      topical nonsteroidal anti-inflammatory drug (NSAID) in photorefractive keratectomy(PRK)\n      using time serial pain scoring."
        }, 
        "brief_title": "Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Myopes Who Have Undergone PRK.", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. at least 19 years of age\n\n          2. simultaneous bilateral PRK schedule\n\n          3. more than 400\u03bcm(including epithelium) of postoperative corneal thickness\n\n          4. less than 150\u03bcm of ablation depth.\n\n        Exclusion Criteria:\n\n          1. a history of ocular surgery or trauma\n\n          2. two-diopter more difference in spherical equivalent (SE) between the eyes, 3.\n             keratoconus or other corneal pathology\n\n        4. use of systemic or topical NSAID within 1 month before the surgery 5. history of\n        allergic reaction to aspirin or other NSAIDs 6. glaucoma or ocular hypertension (> 20\n        mmHg) 7. collagen vascular diseases 8. diabetic retinopathy 9. pregnancy or lactation 10.\n        intraoperative complications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761071", 
            "org_study_id": "4-2012-0440"
        }, 
        "intervention": [
            {
                "arm_group_label": "group KO", 
                "description": "On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular\u00ae, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox\u00ae, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren\u00ae, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.", 
                "intervention_name": "topical ketorolac 0.5% (Acular\u00ae, Allergan Inc, Irvine, CA)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "group DO", 
                "description": "On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular\u00ae, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox\u00ae, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren\u00ae, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.", 
                "intervention_name": "topical diclofenac 0.1% (Voltaren\u00ae, Novartis, Bern, Switzerland)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Diclofenac", 
                "Ketorolac", 
                "Ketorolac Tromethamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Departement of Ophthalmology, Yonsei University College of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Through these postoperative pain score which rated time serially, the effect of pre-treated topical NSAIDs(ketorolac and diclofenac) could be investigated on relieving postoperative pain after PRK.", 
            "measure": "Pain score using visual analog scale(VAS) of each topical NSAIDs pre-treated eyes.", 
            "safety_issue": "No", 
            "time_frame": "Change the VAS level at 6, 18, 24, 36, 48, 72, and 96 hours after ketorolac in photorefractive keratectomy(PRK)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761071"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}